Healthcare company Aventus Health has expanded its Covid-19 test portfolio with the introduction of new variant test.

The Covid-19 variant test has been developed to accurately detect known SARS-CoV-2 variants, in addition to discovering novel variants.

To develop the test, Aventus has used its Next-Generation Sequencing (NGS) technology and the advanced laboratory-developed assay that will help break down the sequence of base pairs, which include the genetic makeup of the various strains of corona virus.

Aventus CEO Oliver Dawoud said: “Our world-class laboratory scientists and technicians are renowned for their innovations in genomics and diagnostics.

“At the onset of the pandemic, Aventus released one of the most accurate COVID-19 RT-PCR tests in the market and went on to make COVID-19 testing widely available through our partnerships.

“To complete our wide array of services, we were able to utilise our state-of-the-art technology to bring to market SARS-CoV-2 variant testing.”

The result provided by the test will help advance the study, as well as track and understand emerging Covid-19 variants and their potential impact on public health.

Aventus, which offers a suite of Covid-19 testing services, will also include reflex testing-to-NGS on all its RT-PCR patient tests that help deliver a positive result to detect currently known variants and new variants that are yet to be discovered.

The company consists of a diverse portfolio of integrated healthcare service companies and clinical care facilities, which serve as a platform for range of cost-effective and advanced solutions.